The Week Ahead In Biotech (March 8-14): Bristol-Myers Awaits FDA Nod For Liver Cancer Combo Therapy, Earnings Flow Continues

Biotech stocks rebounded in the week ended March 6, recovering from the previous week's steep sell-off.

The week was light on news flow, barring some smid-cap earnings and COVID-19 treatment and vaccine news.

The following are key catalysts in the unfolding week that a biotech investor should stay tuned to. 

Conferences

Barclays Global Healthcare Conference: March 10-12 in Miami, Florida.
American Academy of Allergy Asthma and Immunology, or AAAAI, Annual Meeting: March 13-16 in Philadelphia, Pennsylvania.

PDUFA Dates

The FDA is set to rule on Bristol-Myers Squibb Co's BMY sBLA for Opdivo + Yervoy as a treatment option for patients with advanced hepatocellular carcinoma who were previously treated with Bayer AG BAYRY and Onyx Pharma's Nexavar. The PDUFA date has been set for Tuesday.

Clinical Readouts

Blueprint Medicines Corp BPMC is scheduled to present at the AAAAI annual meeting with Phase 2 data for Avapritinib, which is being evaluated for treating indolent and smoldering systemic mastocytosis.

See also: Attention Biotech Investors: Mark Your Calendar For These March PDUFA Dates

Earnings

Monday

• Matinas BioPharma Holdings Inc MTNB (before the market open)
• Minerva Neurosciences Inc NERV (before the market open)
• BioXcel Therapeutics Inc BTAI (before the market open)
• Assertio Therapeutics Inc ASRT (after the close)
• SI-Bone Inc SIBN (after the close)
• Xenon Pharmaceuticals Inc XENE (after the close)
• Organogenesis Holdings Inc ORGO (after the close)
• Deciphera Pharmaceuticals Inc DCPH (after the close)

Tuesday

• Precision BioSciences Inc DTIL (time not provided)
• Akebia Therapeutics Inc AKBA (before the market open)
• Catabasis Pharmaceuticals Inc CATB (before the market open)
• InspireMD Inc NSPR (before the market open)
• ChemoCentryx Inc CCXI (after the close)
• CV Sciences Inc CVSI (after the close)
• Fulgent Genetics Inc FLGT (after the close)
• Sunesis Pharmaceuticals, Inc. SNSS (after the close)
• RA Medical Systems Inc RMED (after the close)
• Protagonist Therapeutics Inc PTGX (after the close)

Wednesday

• Xeris Pharmaceuticals Inc XERS (before the market open)
• Liquidia Technologies Inc LQDA (before the market open)
• Galmed Pharmaceuticals Ltd GLMD (before the market open)
• INmune Bio Inc INMB (before the market open)
• Clearside Biomedical Inc CLSD (after the close)
• Calithera Biosciences Inc CALA (after the close)
• Unity Biotechnology Inc UBX (after the close)
• Navidea Biopharmaceuticals Inc NAVB (after the close)
• Cumberland Pharmaceuticals, Inc. CPIX (after the close)
• BioLife Solutions Inc BLFS (after the close)
• Dynavax Technologies Corporation DVAX (after the close)
• Miragen Therapeutics Inc MGEN (after the close)
• Pfenex Inc PFNX (after the close)
• Thursday
• Aquestive Therapeutics Inc AQST (before the market open)
• Avadel Pharmaceuticals PLC AVDL (before the market open)
• Axsome Therapeutics Inc AXSM (before the market open)
• Aldeyra Therapeutics Inc ALDX (before the market open)
• Selecta Biosciences Inc SELB (before the market open)
• Lexicon Pharmaceuticals, Inc. LXRX (before the market open)
• Provention Bio Inc PRVB (before the market open)
• Protalix Biotherapeutics Inc PLX (before the market open)
• Evofem Biosciences Inc EVFM (before the market open)
• China Biologic Products Holdings Inc CBPO (before the market open)
• Corbus Pharmaceuticals Holdings Inc CRBP (before the market open)
• Pieris Pharmaceuticals Inc PIRS (before the market open)
• X4 Pharmaceuticals Inc XFOR (before the market open)
• Polarityte Inc PTE (before the market open)
• Rubius Therapeutics Inc RUBY (before the market open)
• Agenus Inc AGEN (before the market open)
• ADMA Biologics Inc ADMA (after the close)
• BioDelivery Sciences International, Inc. BDSI (after the close)
• Bellicum Pharmaceuticals Inc BLCM (after the close)
• Celcuity Inc CELC (after the close)
• Lineage Cell Therapeutics Inc LCTX (after the close)
• Chembio Diagnostics Inc CEMI (after the close)
• Harpoon Therapeutics Inc HARP (after the close)
• Flexion Therapeutics Inc FLXN (after the close)
• Neoleukin Therapeutics Inc NLTX (after the close)
• Rockwell Medical Inc RMTI (after the close)
• Inovio Pharmaceuticals Inc INO (after the close)
• Savara Inc SVRA (after the close)
• Ocular Therapeutix Inc OCUL (after the close)
• Y-mAbs Therapeutics, Inc YMAB (after the close)

Friday

• PLx Pharma Inc PLXP (before the market open)
• Achieve Life Sciences Inc ACHV (before the market open)

IPOs

Imara, a biopharma company that is developing therapies for rare hemoglobinopathies, has filed to offer 4.45 million shares in an IPO, to be priced between $16 and $18. The company seeks to list its shares on the Nasdaq under the ticker symbol "IMRA."

IPO Quiet Period Expiry

Revolution Medicines Inc RVMD

Related Link: How The COVID-19 Outbreak Is Benefiting Biotech Investors